exocrine pancreatic insufficiency newsletter

A degenerative disease, Exocrine Pancreatic Insufficiency (EPI), is a consequence of insufficient production and secretion of pancreatic digestive enzymes, which leads to maldigestion in the duodenum. Exocrine Pancreatic Insufficiency (EPI) is a medical condition characterized by the inadequate production or delivery of pancreatic enzymes necessary for proper digestion. The pancreas has both endocrine (hormone-producing) and exocrine (enzyme-secreting) functions. In EPI, the exocrine component is compromised, leading to significant digestive and nutritional problems.

Know more about the Exocrine Pancreatic Insufficiency, its pathophysiology, manifestations, epidemiological scenario, and available treatment modalities by filling up the form towards the right. The development of more effective enzyme formulations and research into early biomarkers for pancreatic dysfunction is ongoing. There is also growing interest in gut microbiome research, as EPI alters gut flora and could impact overall health.

Get insights into the Exocrine Pancreatic Insufficiency market landscape, upcoming therapies, and key pharma companies transforming EPI market outlook through our newsletter.

Through its newsletter, DelveInsight aims to provide rich insights into several diseases for a better understanding of the disease, their therapies, and market trends.

Download our newsletters and subscribe to our page to keep yourself updated on the latest events of significance in the field.

Stay tuned for more